Regeneron Pharmaceuticals (REGN)
(Delayed Data from NSDQ)
$1,014.59 USD
-25.68 (-2.47%)
Updated Oct 3, 2024 04:00 PM ET
After-Market: $1,013.52 -1.07 (-0.11%) 7:58 PM ET
3-Hold of 5 3
C Value F Growth C Momentum F VGM
Price, Consensus and EPS Surprise
REGN 1,014.59 -25.68(-2.47%)
Will REGN be a Portfolio Killer in October?
Zacks Investment Research is releasing its prediction for REGN based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for REGN
Here's Why You Should Add ALNY Stock to Your Portfolio Right Now
Should You Invest in the iShares Biotechnology ETF (IBB)?
REGN: What are Zacks experts saying now?
Zacks Private Portfolio Services
Sanofi, Regeneron's Dupixent Gets FDA Approval for COPD
Bayer Submits Application for Label Expansion of Prostate Cancer Drug
AMGN Stock Falls Despite Upbeat Data on Immunology Drugs: Here's Why
Other News for REGN
(REGN) - Analyzing Regeneron Pharmaceuticals's Short Interest
November 22nd Options Now Available For Regeneron Pharmaceuticals
Insider Sale: Director Arthur Ryan Sells Shares of Regeneron Pharmaceuticals Inc (REGN)
Market Whales and Their Recent Bets on REGN Options
Disney upgraded, JPMorgan downgraded: Wall Street's top analyst calls